We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Proteomic Workflow Maps Microbial and Host Responses in Intestinal Inflammation

By LabMedica International staff writers
Posted on 05 Aug 2026

The intestinal microbiome influences digestion, metabolism, and immunity, yet its complexity makes functional measurements difficult to obtain. More...

DNA surveys can indicate which organisms and potential pathways are present, but they do not reveal which activities are engaged or how the host responds. Laboratories therefore need protein-level readouts that track microbial function alongside host tissue dynamics across disease. A new study shows strategies for concurrently measuring thousands of microbial and host proteins during intestinal inflammation.

At the University of Vienna, researchers systematically compared five state-of-the-art mass spectrometry approaches using human fecal samples and identified methodological strategies that provide high sensitivity, reproducibility, and functional insight. The work centers on metaproteomics, enabling simultaneous capture of microbial proteins and host proteins from the same specimens. The study also assessed whether these analytical strategies maintain performance in a biologically relevant setting.

Proteins provide the missing functional information by revealing which microbial activities are currently active, how different microbiome members contribute, and how the host responds. By pairing metaproteomic profiles with organismal lists from DNA sequencing, investigators can resolve activity rather than only potential. This framework yields concurrent readouts of microbial function and host response from the same samples.

The researchers then evaluated performance in a biologically relevant setting by measuring microbial and host proteins throughout disease progression and recovery. The best-performing methods captured highly concordant host and microbial responses during the onset and recovery of intestinal inflammation, demonstrating that technological advances can translate into robust biological insights.

Collaborative contributors included the University of Vienna Bruker Daltonics Center of Excellence for Metaproteomics and the Systems Biology of Pain Laboratory (Division of Pharmacology & Toxicology) at the University of Vienna.

The findings are described in Nature Communications in an article titled “Systematic evaluation of PASEF acquisition strategies in complex metaproteomes” (2026). The study highlights methodological choices that enable large-scale, simultaneous characterization of microbial and host proteomes from human fecal specimens.

“Metaproteomics allows us to see what microbial communities are actually doing, rather than simply which microbes are present. By identifying the most suitable analytical strategies, we hope to make future microbiome research more sensitive, reproducible and accessible across medicine, environmental science and biotechnology,” said Feng Xian, first author of the study.

“Developing better technologies is essential if we want to answer the next generation of questions in microbiome research. Only by listening to the musical score played by microbes can we begin to understand why the audience—the host—responds in a particular way. This will transform our understanding of the microbiome's role in human health. We are already applying these advances in international clinical collaborations to study the involvement of microbiomes in neurological, metabolic and autoimmune diseases,” said David Gomez-Varela, director of the CoE.

Related Links
University of Vienna


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Aspiration System
VACUSAFE
New
Gold Member
Serum Indices Control
Acusera Serum Indices Control
Food Allergy Screening ELISA Kit
Allerquant 14G B ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: A large, international study led by City of Hope found that the new, investigational liquid biopsy, called PANXEON, was highly sensitive in detecting stage 1 and 2 pancreatic cancer and had a low rate of false positives. The test was also able to identify high-grade dysplasia, a precancerous condition of the pancreas, potentially enabling intervention before cancer develops. (Photo courtesy of City of Hope)

Multi-Biomarker Blood Test Shows Promise for Early Pancreatic Cancer Detection

Pancreatic cancer has the lowest survival rates of any cancer, with only 14% of patients alive five years after diagnosis. The disease is typically discovered after it has spread, and an estimated 90%... Read more

Molecular Diagnostics

view channel
Image: NTM are about 200 environmental bacteria found in soil and water that can cause chronic, tuberculosis-like lung infections but are distinct from the Mycobacterium tuberculosis complex (Image Credit: Adobe Stock)

Rapid CRISPR Test Identifies Nontuberculous Mycobacteria Species from Respiratory Samples

Chronic lung infections caused by nontuberculous mycobacteria (NTM) are increasingly recognized but frequently mistaken for tuberculosis, complicating diagnosis and care. These infections may affect as... Read more

Immunology

view channel
Image: Although many people harbor latent Epstein-Barr virus (EBV), growing evidence has linked the virus to MS pathobiology (Image Credit: Adobe Stock)

Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead

Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more

Pathology

view channel
image Credit: iStock

Tumor Budding Grading May Predict Chemotherapy Benefit in Resected Lung Squamous Cancer

Outcomes after resection for lung squamous cell carcinoma (SqCC) vary substantially, and the uneven benefit of adjuvant chemotherapy complicates postsurgical treatment decisions. Pathologic markers that... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: The acquisition adds Convergent Genomics’ UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio (Photo courtesy of Convergent Genomics)

Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities

Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.